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Background: Atrial ﬁbrillation (AF) is the most common cardiac arrhythmia and
a major cause of morbidity and mortality secondary to cardioembolic stroke. Percu-
taneous closure of the left atrial appendage (LAA) has emerged as an alternative to
anticoagulation therapy for the prevention of cerebrovascular events in patients with
AF and a contraindication or difﬁculties for oral anticoagulation. This study describes
the feasibility, in hospital and follow up results of the transcatheter closure of the LAA
with the Amplatzer Cardiac Plug(ACP; StJude,Minneapolis; MN) in an initial Latin
American experience.
Methods: Physician initiated voluntary registry, including 60 consecutive patients
with AF at high risk for cardioembolic stroke, from different Latin American hospitals
that were treated with the ACP, from August 2009 to June 2012. The procedures were
performed under general anesthesia, transesophageal ecocardiography (TEE) and
ﬂuoroscopic guidance. Clinical and TEE follow up was performed at 30 days, and
clinical follow up thereafter.
Results: 60 patients were included. Age 728.7 years;male70%; hyper-
tensive78%;congestive heart failure32.17%; CHADS2 score 3.151.1; contraindica-
tions to oral anticoagulation 64.3% LAA neck diameter was 20.33.8 mm by TEE
and 22.63.2 by angiography. LAA occlusion was attempted and successfully ach-
ieved in all 60 patients, and in 3 cases, simultaneous closure of the LAA and PFO was
performed. The implanted device size was 252.9 mm. There were serious in hospital
complications in 5 patients (8.3%). 1 patient experienced device embolization that
required surgical retrieval, and 4 (6.6%) patients presented severe pericardial effusion
(SPE) requiring pericardiocentesis. For patients with (SPE) hospitalization was longer
4.251.25, vs 2.772.10 days for patients without SPE p¼0.174. There were not in
hospital deaths, stroke, or myocardial ischemia. No new events were reported at 30
days clinical follow up. 88% of patients underwent TEE at 30-45 days without
evidence of ﬂow to the LAA or thrombus on device. Median follow up was 12.5
months, without strokes.
Conclusions: In this initial experience, percutaneous closure of the LAA with the
ACP in patients with AF at high risk of stroke, was feasible, with a high technical
success and in hospital complications rate similar to previous reports with these and
other devices during the learning phase of the procedure. The results at follow up are
encouraging.
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Background: Device selection for percutaneous atrial septal defect (ASD) closure is
usually based on balloon sizing (BS) of the defect. This step is crucial to avoid under
or oversizing and resultant complications. Although three-dimensional (3D) trans-
esophageal echocardiography (TEE) has been used to guide the procedure, its role in
determining accurate device selection remains an open area for research. We studied
the use of 3D TEE as a possible surrogate for BS for proper device selection in ASD
closure.
Methods: Patients underwent percutaneous ASD closure under general anesthesia
and 3D TEE monitoring. Largest and smallest diameters of the ASD, the areas of the
defect, sizing balloon and selected device waist were recorded as well as the char-
acteristics of the interatrial septum (IAS). BS with the PTS balloon was performed
using the "stop-ﬂow" technique. A Cera device (Lifetech, China) the same size of the
BS diameter or 1 mm larger was selected for implantation. Linear regression analyses
were employed to determine what was the best baseline parameter on 3D TEE to
predict adequate device selection. T tests or Mann-Whitney tests were used as
applicable.
Results: Twenty-ﬁve adult patients (mean age: 4215 years) were enrolled. Six had
redundant or aneurysmal IAS. In the entire cohort ASDs were oval measuring
19.66.5 X 14.24.5mm (p<0.001). The BS and selected device waist diameters
were 22.36.0 and 21.95.8 mm, respectively (p¼NS). The area of the ASD, sizing
balloon and device waist were 262.8144.7, 416.4  226.6, 402.2  196.9 mm2,
respectively (p¼NS between balloon and device areas). After device release waistJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrdiameter and area were 19.6  5.2mm (p¼NS) and a median of 281mm2 (73-677)
(p¼0.081), respectively, similar to pre-implantation values. In patients with thicker,
non-redundant IAS there was an excellent correlation between the largest ASD
diameter (R¼ 0,954; R2¼ 0,911) and the ASD area (R¼ 0,929; R2¼ 0,864) on 3D
TEE and the selected device diameter. A poor correlation was observed for patients
with redundant/aneurysmal IAS. The regression equations that were obtained for
proper device size selection were Device size (mm)¼ (Largest 3D TEE ASD diameter
X 0.888) + 3.911 mm and Device size (mm) ¼ 11,859 + (0,0374 X 3D TEE ASD
area).
Conclusions: The largest ASD diameter and the ASD area on 3D TEE were excellent
surrogates for BS in patients with thicker, non-redundant IAS. The application of this
new method for device selection may help to expedite the procedure and avoid
oversizing. These observations should be validated in prospective trials.
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Background: Endocarditis is a risk factor for and sequelae of surgical prosthetic
paravalvular leaks (PVLs). The modiﬁed Duke Criteria is the gold standard for
diagnosing infective endocarditis. Nonetheless, it has never been evaluated for pros-
thetic valve endocarditis (PVE). Concern remains regarding the safety of percutaneous
PVL closure in patients at high risk for PVE.
Methods: We evaluated patients from January 2012 to June 2013 who presented for
symptomatic PVL closure. High-risk for PVE was deﬁned as a modiﬁed Duke
Criteria that met at least 1 major and 1 minor criteria aside from a predisposing heart
condition. Gallium SPECT (24  48 hours) or PET imaging were fused with cardiac
CT. Patients with positive studies either underwent surgical valve replacement
(SVR) or 6 weeks of intravenous antibiotics followed by repeat nuclear study, with
subsequent intervention if resolved. Patient with negative studies underwent
percutaneous closure.
Results: 62 patients were evaluated with 11 patients deemed high risk for PVE
(6513 years, 100% heart failure, 37% hemolysis). Deﬁnite criteria were met in 27%
(2 major n¼2; 1 major 3 minor n¼1). Two patients had positive nuclear studies and
underwent SVR and 1 patient had a negative study and underwent SVR after
unsuccessful closure, with negative surgical cultures. Possible criteria were met in
72% (1 major 1 minor or 2 minor with echocardiogram concerning for abscess n¼2; 1
major 2 minor n¼6). 2 patients with abnormal echocardiograms had positive nuclear
studies and died (1 intraoperative with positive cultures, 1 inoperable). Two patients
had positive studies and successful closure after antibiotics and negative repeat
imaging. The remaining 4 patients had negative nuclear studies and successful closure.
On follow-up (8.58 months), no PVE was identiﬁed with improvement in NYHA by
1 and complete hemolysis resolution.
Conclusions: Early experience of Gallium SPECT/CT or PET/CT identiﬁes a poten-
tial role in the assessment of PVE in PVL patients. Further evaluation on the utility of
nuclear fusion imaging in this patient population is necessary.TCT-692
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Background: The WATCHMAN left atrial appendage (LAA) Closure Device has
been shown to be at least equivalent to anticoagulation for stroke prevention in
patients with non-valvular atrial ﬁbrillation (NVAF). A newer, (fourth) generation
WATCHMAN device (with a less traumatic distal tip and option of recapture and
redeployment) was designed to facilitate delivery and improve the safety proﬁle,
particularly the incidence of pericardial effusions. The aim of this study was to
evaluate the feasibility and safety of the newer (fourth) generation WATCHMAN left
atrial appendage (LAA) closure device.
Methods: This was a prospective, single-center, non-randomized study of LAA
closure in 36 patients with NVAF.
Results: Between February 2010 and June 2011, 36 patients (mean age: 72  16
years, male: 66.7%, median CHADS2 of 2.83, median CHA2DS2-VASc of 4.5)
with NVAF underwent percutaneous LAA closure with the newer (fourth)acts/POSTER/Non-valvular Structural Heart Disease B211
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Sgeneration WATCHMAN LAA closure device. Of the 36 patients, the new device
was implanted in 34 (94.4%). In two patients (5.6%), device closure was attempted
but unsuccessful due to an unfavorable LAA anatomy (early separation into multiple
lobes in one and acute LAA angulation in the second). In these cases closure was
performed successfully with a different closure system. Though in eight patients
partial and in fourteen full recaptures were needed prior to ﬁnal release, there was no
pericardial effusion. Mean procedural time was 50  45 minutes. No device-related
adverse events occurred during the procedure and accurate device placement was
achieved in all implanted patients. During the follow-up of 12 months, three
ischemic strokes (8.3%), one hemorrhage stroke (2.7%), one TIA (2.7%) and three
deaths (8.7%) occurred. Device-associated thrombus formation was seen in one
patient (2.7%) at the six-month follow-up treated with low molecular weight
heparin.
Conclusions: LAA closure with the newer (fourth) generation WATCHMAN device
is feasible and safe. The atraumatic distal end may reduce the incidence of pericardial
effusion during implantation.
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Background: Recent study results present left atrial appendage (LAA) occluders as
an alternative to oral anticoagulation for stroke prevention in patients with atrial
ﬁbrillation. Several devices with different designs (speciﬁcally different anchoring
methods and diameters) are being tested in clinical and animal trials with good results.
Device anchoring and achieving sufﬁcient seal remain challenges, considering the
diverse morphologies of the LAA, but must be achieved in order to prevent residual
ﬂow and possible associated thrombotic events. There are currently no standard
guidelines or norms for in-vitro assessment and comparability of LAA occluders and
their function.
Methods: In order to design a test system for the in-vitro assessment of LAA
occluder function, a design study and review of literature and CT-data were per-
formed. Additionally, anatomical studies on LAAs of porcine hearts were performed
to better incorporate the surface structure and mechanical properties into the test
setup.
Results: A modular in-vitro test system with the possibility of integrating exact
physiological models of the LAA was developed. The system allows for integration
and exchange of different LAA morphologies cast from silicone or native animal
anatomies and has the possibility to assess permeability, seal and anatomical ﬁt of
LAA occluders.
Conclusions: Standardized tests are essential during the establishment of novel device
based therapies, to ensure comparability and the fulﬁllment of basic requirements. The
in-vitro test setup for LAA occluders presented here allows for assessment and
optimization of LAA occluders.Mitral Valve Disease and Treatment
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Acute Hemodynamic effects of the MitraClip System. Focus on grade of MR,
stroke volume, LA-, PA- and PCW- pressure. Analyzing 330 MitraClip
procedures at the AK St. Georg, Hamburg
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Background: Hemodynamic changes after MitraClip procedure are rarely described
till today. Aim of this work was to improve the understanding of the acute hemo-
dynamic effects.
Methods: Till today more than 330 Patients have been treated with the MitraClip
System at the AK St. Georg in Hamburg. Hemodynamics have been evaluated with
Swan Ganz catheterization and thermodilution method directly before and after
Clipping. The functional result was assessed 6 weeks, 6 months and 12 months after
the MitraClip procedure.B212 JACC Vol 62/18/Suppl B j October 27–NovemberResults: 314 out of 330(95.2%) patients could be treated successfully (MR post 2).
30 day mortality was 7%. MR was reduced signiﬁcantly from 3.0(0.3) to 1.1(1.1)
(p<0.001), needing an average of 1.4 Clips(0.6). Cardiac output(CO) increased
from 3.7l/min(1.1) to 4.7l/min(1.3) directly after the procedure (p<0.001). Stroke
volume(SV) increased from 62.4ml(18.7) to 80.7ml(26.9) (p<0.001). Systolic
pulmonary artery pressure (PAPs) increased slightly from 39.9mmHg(12.5) to
42.2mmHg(12.2) (p<0.05). Wedge pressure (PCWP, mean) fell from
16.8mmHg(7.8) before to 15.7mmHg(6.5) post MitraClip (p<0.05). Left atrial
pressure (LA, mean) was reduced signiﬁcantly (p<0.001) from 16.1mmHg(6.9) to
13.2mmHg(6.1). Grade of dyspnea by NYHA fell signiﬁcantly as well (3.2(0.5)
baseline, 2.1(0.7) after 6 months and 2.2(0.6) after 12 months), p<0.001. Grade of
MR assessed by echo was reduced stable and signiﬁcantly from 3.1(0.3) before to
1.1(0.6) directly after and 1.8(0.7) after 6 months, p<0.001.
Conclusions: The MitraClip procedure shows a stable reduction of MR combined
with a stable improvement of the clinical symptom dyspnea. We’ve shown that this
non open chest treatment of MR improves the CO and SV of up to 27% while
reducing LA pressure signiﬁcantly. If these ﬁndings have a prognostic impact is part
of running investigation.
TCT-695
A Gender-Speciﬁc Look at MitraClip Therapy in Surgical High-Risk Patients:
Acute and Long-Term Outcomes
Michael Schlüter1, Daniel Lubs1, Edith Lubos1, Volker Rudolph2, Hendrik Treede1,
Johannes Schirmer1, Lenard Conradi1, Hermann Reichenspurner1, Stephan Baldus2,
Stefan Blankenberg1, Britta Goldmann1
1University Heart Center Hamburg, Hamburg, Germany, 2University Hospital of
Cologne, Cologne, Germany
Background: In Europe, MitraClip (MC) therapy for signiﬁcant mitral regurgitation
(MR) is increasingly being performed, particularly in elderly patients at high surgical
risk. Outcomes emphasizing differences between men and women are lacking. We
present a high-volume single-center retrospective analysis of outcomes according to
gender.
Methods: By 01/2013, 361 consecutive patients (75  9 years, 227 men [M; 63%],
134 women [F; 37%]) with MR 3+/4+ had undergone MC therapy at the University
Heart Center Hamburg. All patients were adjudicated by heart team consensus as not
amenable to surgery.
Results: Baseline conditions were signiﬁcantly more adverse in M than in F, with
higher log. EuroSCORE, lower LVEF, and higher prevalence of cardiomyopathy,
hypercholesterolemia, diabetes, coronary artery disease, renal failure, and functional
MR in the former. Procedures were successful (discharge MR 2+) in 207 M (91%)
and 118 F (88%, p¼NS). Follow-up information was available in 205 M (90%) and
116 F (87%) at a median of 12.7 (range, 0.3-41) and 13.6 (0.4-39) months, respec-
tively (p¼NS). No signiﬁcant differences in the prevalence of MR 2+ and of NYHA
functional class II were observed at 12 months (MR: M 91%, F 85%; NYHA: M
60%, F 50%) and 24 months (MR: M 91%, F 80%; NYHA: M 62%, F 49%). Overall,
cumulative survival was not different between M and F (p[logrank]¼0.12), but
survival curves diverged signiﬁcantly in favor of F after 12 months (p¼0.03 by
landmark analysis). Independent predictors of death on multivariate Cox regression
analysis were renal failure and MC failure in M, yet renal failure and dilated
cardiomyopathy in F. Rehospitalizations were frequent (M 54% and F 41% at 18
months), but not signiﬁcantly different between M and F. MC failure was predictive of
rehospitalizations in both genders.
Conclusions: MC therapy appears to be equally effective, acutely as well as in the
long term, in M and F at high surgical risk. Increased mortality after 1 year in M is
likely related to higher comorbidity and poorer LV function and requires further study.
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Background: The aim of this study is to investigate the predictors of quality of life
(QoL) restoration 1 year after MitraClip implantation in heart failure patients with
FMR in our single center experience.
Methods: From October 2008, 109 consecutive patients with FMR underwent
MitraClip implantation (mean age 699 years). FMR was ischemic in 75%. All
patients underwent standardized assessment of mitral valve anatomy and functional
status. Preprocedural QoL was assessed by Minnesota Living with Heart Failure
Questionnaire (MLHFQ). Logistic EuroScore was 2216%; 82% pts were in NYHA
class III-IV. Mean EF was 2811%; LVEDD was 688 mm. A cut-off of 14 points
with MLHFQ was used to deﬁne QoL restoration 1 year after the procedure (corre-
sponding to the mean MLHFQ observed in a NYHA I-II heart failure Italian pop-
ulation with mean age of 61 years).1, 2013 j TCT Abstracts/POSTER/Mitral Valve Disease and Treatment
